JP2017500334A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500334A5
JP2017500334A5 JP2016541280A JP2016541280A JP2017500334A5 JP 2017500334 A5 JP2017500334 A5 JP 2017500334A5 JP 2016541280 A JP2016541280 A JP 2016541280A JP 2016541280 A JP2016541280 A JP 2016541280A JP 2017500334 A5 JP2017500334 A5 JP 2017500334A5
Authority
JP
Japan
Prior art keywords
alkyl
aliphatic
independently
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500334A (ja
JP6883988B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071644 external-priority patent/WO2015095783A1/en
Publication of JP2017500334A publication Critical patent/JP2017500334A/ja
Publication of JP2017500334A5 publication Critical patent/JP2017500334A5/ja
Application granted granted Critical
Publication of JP6883988B2 publication Critical patent/JP6883988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541280A 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Active JP6883988B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361919394P 2013-12-20 2013-12-20
US201361919390P 2013-12-20 2013-12-20
US61/919,390 2013-12-20
US61/919,394 2013-12-20
US201462075743P 2014-11-05 2014-11-05
US62/075,743 2014-11-05
PCT/US2014/071644 WO2015095783A1 (en) 2013-12-20 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019193538A Division JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Division JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Publications (3)

Publication Number Publication Date
JP2017500334A JP2017500334A (ja) 2017-01-05
JP2017500334A5 true JP2017500334A5 (enExample) 2018-02-01
JP6883988B2 JP6883988B2 (ja) 2021-06-09

Family

ID=53403769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541280A Active JP6883988B2 (ja) 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Country Status (11)

Country Link
US (2) US10329301B2 (enExample)
EP (2) EP3083569B1 (enExample)
JP (3) JP6883988B2 (enExample)
CN (2) CN112409363B (enExample)
AU (1) AU2014368961B2 (enExample)
CA (2) CA3123897C (enExample)
IL (1) IL246261B (enExample)
MX (2) MX381561B (enExample)
NZ (2) NZ760341A (enExample)
WO (1) WO2015095783A1 (enExample)
ZA (1) ZA201605027B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10449181B2 (en) 2016-08-25 2019-10-22 Sarah E. Labance Treatment of autism and autism spectrum disorders (ASD)
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) * 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
CA3129749A1 (en) * 2019-02-13 2020-08-20 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
WO2022011318A1 (en) * 2020-07-10 2022-01-13 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
CN113284553B (zh) * 2021-05-28 2023-01-10 南昌大学 一种用于治疗药物成瘾的药物靶点结合能力测试方法
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH603545A5 (enExample) 1972-04-20 1978-08-31 Merz & Co
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
EP0586551A1 (en) 1991-05-24 1994-03-16 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (enExample) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CN1079670C (zh) 1994-03-02 2002-02-27 阿克佐诺贝尔公司 舌下或颊给药的药物组合物
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
AU1041599A (en) 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
WO2000027849A2 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
KR100694682B1 (ko) 1999-03-03 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 4-치환 피페리딘 유도체 불화물
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
JP2004527500A (ja) 2001-03-01 2004-09-09 ファイザー・プロダクツ・インク 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンeとgabaa逆アゴニストの併用
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
CA2473536A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
EP1532120B1 (en) 2002-08-13 2009-01-14 MERCK SHARP & DOHME LTD. Phenylpyridazine derivatives as ligands for gaba receptors
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
NZ540288A (en) 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
US20050113458A1 (en) 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
CA2578953A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
DE602005008633D1 (de) 2004-10-12 2008-09-11 Hoffmann La Roche Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen
JP4783375B2 (ja) 2004-10-20 2011-09-28 エフ.ホフマン−ラ ロシュ アーゲー イミダゾベンゾジゼピン誘導体
MX2007004640A (es) * 2004-10-20 2007-06-08 Hoffmann La Roche Derivados de benzodiazepina sustituidos con halogeno.
ES2307230T3 (es) 2004-12-14 2008-11-16 F. Hoffmann-La Roche Ag Imidazo-benzodiacepinas tetraciclicas como moduladores de los receptores gaba.
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1888594A2 (en) 2005-05-16 2008-02-20 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP2682481A3 (en) 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
ATE477255T1 (de) 2005-10-11 2010-08-15 Hoffmann La Roche Imidazobenzdiazepinderivate
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
BRPI0912587A2 (pt) 2008-09-24 2015-07-28 Du Pont "composto, composição fungicida e método para o controle de doenças vegetais causadas por patógenos fúngicos de plantas"
MX2011002915A (es) 2008-09-25 2011-04-21 Vive Nano Inc Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
JP2012524065A (ja) 2009-04-17 2012-10-11 ゼノポート,インコーポレーテッド GABAB受容体リガンドとしてのγ−アミノ酪酸誘導体
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン,インク. 認知増強のための化合物と組成物、製造方法、および治療方法
NZ608592A (en) * 2010-11-05 2015-08-28 Hoffmann La Roche Use of active pharmaceutical compounds for the treatment of central nervous system conditions
BR112013012072A2 (pt) * 2010-11-15 2016-08-16 Agenebio Inc derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
WO2012161133A1 (ja) 2011-05-20 2012-11-29 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
US20150224094A1 (en) 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson

Similar Documents

Publication Publication Date Title
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2018521034A5 (enExample)
JP2021528427A5 (enExample)
JP6466348B2 (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
JP2019034943A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019519598A5 (enExample)
JP2020528889A5 (enExample)
JP2014503574A5 (enExample)
JP2019518071A5 (enExample)
JP2019518766A5 (enExample)
JP2019515952A5 (enExample)
JP2018507877A5 (enExample)
JP2013544846A5 (enExample)
JP2017518959A5 (enExample)
JP2013542267A5 (enExample)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2011500621A5 (enExample)
JP2012532112A5 (enExample)
EA023824B1 (ru) ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
JP2020512389A5 (enExample)
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017176962A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
PE20220964A1 (es) Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas
JP2017508733A5 (enExample)